XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a report released on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($0.22) for the quarter, up from their prior forecast of ($0.24). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.77) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals’ FY2026 earnings at ($0.79) EPS, FY2028 earnings at ($0.26) EPS and FY2030 earnings at $3.29 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 64.95% and a negative net margin of 568.80%.The company had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Leerink Partners began coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Wells Fargo & Company began coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.70.

X4 Pharmaceuticals Stock Down 8.4%

XFOR stock opened at $4.25 on Tuesday. The firm has a 50 day moving average of $4.03 and a 200 day moving average of $3.95. The stock has a market capitalization of $400.86 million, a PE ratio of -3.54 and a beta of 0.37. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.83.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of X4 Pharmaceuticals stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. This trade represents a 4.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.13% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at approximately $917,000. Pettinga Financial Advisors LLC purchased a new position in X4 Pharmaceuticals in the second quarter valued at $47,000. Perceptive Advisors LLC raised its position in shares of X4 Pharmaceuticals by 6.7% in the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock worth $27,826,000 after acquiring an additional 423,196 shares during the period. Bank of America Corp DE boosted its stake in shares of X4 Pharmaceuticals by 321.3% during the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after acquiring an additional 114,915 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new stake in shares of X4 Pharmaceuticals during the 1st quarter valued at about $46,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.